Abacus Health Products Expands Its CBDMEDIC Offering To Additional Major Retail Pharmacy Chain

Abacus Health Products Expands Its CBDMEDIC Offering To Additional Major Retail Pharmacy Chain

WOONSOCKET, R.I. & TORONTO--(BUSINESS WIRE)--Abacus Health Products, Inc. (CSE: ABCS, OTCQX:ABAHF) (“Abacus” or the “Company”) nowadays introduced that it has acquired a purchase order from a further most important country wide pharmacy chain in the United States, that allows you to be offering products from its CBDMEDIC product line. The merchandise will release across 18 states into 2,400 retail shops throughout the U.S.

The chain could be adding three particular products from the CBDMEDIC product line to its shelves: Back & Neck Pain Relief Ointment, Active Sport™ Pain Relief Stick and Muscle & Joint Pain Relief Spray. The products are deliberate to be rolled-out in January 2020 and the chain has also indicated its goal to feature a further CBDMEDIC SKU at a later time while shelf space becomes available.

With the addition of these places the CBDMEDIC line of merchandise will be available in over 20 retail chains and about 7,000 stores across the United States.

“The addition of this national chain marks an important milestone as our products will now be sold by the three largest retail pharmacy chains in the United States. This is a huge win for Abacus and its consumer product line, CBDMEDIC. The recent announcements we’ve made regarding retail store growth are indicative of the inflection point we’ve been waiting for and we expect acceleration in the adoption of our products by the F/D/M channel in the next several quarters,” said Perry Antelman, CEO of Abacus.

The chains in which CBDMEDIC will now be available represent over 34,500 stores. Abacus’ penetration rate will stand at approximately 20% following the above-mentioned roll-out in January and the Company expects this rate to continue to increase over the coming quarters as its retail partners expand their rollouts to additional locations.

Forward-Looking Statements

This news release carries ahead-looking statements or records (together, “ahead-searching statements”) inside the that means of applicable securities law, inclusive of, with out problem, statements relating to assured purchase orders or next orders from retail chains and the execution of the Company’s growth method. Forward-looking statements are primarily based on some of assumptions and are problem to some of dangers and uncertainties, many of which are past the Company’s control, that might cause real results and events to differ materially from the ones that are disclosed in or implied via such ahead-searching statements, together with assumptions concerning the Company’s ability to efficiently perform its business, marketplace and financial conditions, commercial enterprise prospects or possibilities, future plans and techniques, expected events and developments, and regulatory adjustments that could have an effect on the Company and its clients and industry.

There may be no assurance that real consequences will now not differ materially from the ones expressed or implied in forward-looking statements. Undue reliance ought to now not be positioned on ahead-searching statements. Additional statistics approximately these dangers, uncertainties and assumptions is contained under “Risk Factors and Uncertainties” in the Company’s annual facts form dated April 12, 2019, which is available beneath the Company’s SEDAR profile at www.Sedar.Com. Each ahead-looking statement speaks best as of the date hereof, and the Company undertakes no responsibility to accurate or replace any forward-looking assertion, whether or not as a end result of latest records, future events or in any other case, except as required via relevant law.

About Abacus Health Products, Inc.

Abacus is engaged in the development and commercialization of over-the-counter (OTC) registered topical medications with active pharmaceutical ingredients and which contain organic and natural ingredients, including a cannabinoid-rich hemp extract containing CBD from the Cannabis sativa L plant. Abacus’ products are aimed at the rapidly growing markets for topical pain relief and therapeutic skincare and are based on proprietary patent-pending technologies developed by Abacus. Abacus’ formulations combine advanced science with organic and natural ingredients to provide safe relief. Abacus currently offers two lines of products: CBD CLINIC™, marketed to the professional practitioner market, and CBDMEDIC™, marketed to the consumer market. Abacus’ products are offered across the United States and are produced by a contract manufacturer in a cGMP compliant and audited manufacturing facility.